Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
HKSE:02190'
s EV-to-FCF Range Over the Past 10 Years
Min: -402.53 Med: -12.75 Max: 21.76
Current: 14.66
During the past 7 years, the highest EV-to-FCF of Zylox-Tonbridge Medical Technology Co was 21.76. The lowest was -402.53. And the median was -12.75.
HKSE:02190's EV-to-FCF is ranked better than 73.15% of 406
companies
in the Medical Devices & Instruments industry
Industry Median: 25.2
vs HKSE:02190: 14.66
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Zylox-Tonbridge Medical Technology Co's PE Ratio (TTM) for today is calculated as:
Zylox-Tonbridge Medical Technology Co's share price for today is HK$19.95.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zylox-Tonbridge Medical Technology Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.829.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Zylox-Tonbridge Medical Technology Co EV-to-FCF Related Terms
Zylox-Tonbridge Medical Technology Co EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co EV-to-FCF Chart
For the Medical Devices subindustry, Zylox-Tonbridge Medical Technology Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zylox-Tonbridge Medical Technology Co EV-to-FCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zylox-Tonbridge Medical Technology Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Zylox-Tonbridge Medical Technology Co's EV-to-FCF falls into.
Zylox-Tonbridge Medical Technology Co's current Enterprise Value is HK$4,415 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zylox-Tonbridge Medical Technology Co's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was HK$301 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zylox-Tonbridge Medical Technology Co (HKSE:02190) has a EV-to-FCF of 14.66 as of Aug. 17, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. According to the industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #109 out of 406 companies in the Medical Devices & Instruments industry, placing it in the top 26.8%.
Is Zylox-Tonbridge Medical Technology Co's EV-to-FCF too high?
Zylox-Tonbridge Medical Technology Co's current EV-to-FCF is 14.66. The Medical Devices & Instruments industry median EV-to-FCF is 25.20. Zylox-Tonbridge Medical Technology Co's value of 14.66 is 41.8% below this industry median. Based on the distribution chart, Zylox-Tonbridge Medical Technology Co ranks #109 out of 406 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zylox-Tonbridge Medical Technology Co has a GF Score™ of 82/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zylox-Tonbridge Medical Technology Co's EV-to-FCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Zylox-Tonbridge Medical Technology Co ranks #109 out of 406 companies for EV-to-FCF. This puts Zylox-Tonbridge Medical Technology Co in the upper half of its industry. The industry median EV-to-FCF is 25.20. Zylox-Tonbridge Medical Technology Co's value of 14.66 is 41.8% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Devices & Instruments company?
The median EV-to-FCF among Medical Devices & Instruments companies is 25.20, based on 406 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zylox-Tonbridge Medical Technology Co's current EV-to-FCF of 14.66 is 41.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Zylox-Tonbridge Medical Technology Co and its competitors. For the Medical Devices & Instruments industry, the median EV-to-FCF is 25.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zylox-Tonbridge Medical Technology Co's current EV-to-FCF is 14.66. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zylox-Tonbridge Medical Technology Co stock overvalued right now?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co (HKSE:02190) is currently considered Significantly Undervalued. The stock's GF Value™ is HK$35.80, compared to a current price of HK$19.95 — trading 44.3% below its estimated fair value. The current EV-to-FCF is 14.66 and 41.8% below the Medical Devices & Instruments industry median of 25.20. Zylox-Tonbridge Medical Technology Co's overall GF Score™ is 82/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Zylox-Tonbridge Medical Technology Co (HKSE:02190), the current EV-to-FCF is 14.66 as of Aug. 17, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zylox-Tonbridge Medical Technology Co (HKSE:02190) Overvalued in 2026?
Based on GuruFocus' analysis, Zylox-Tonbridge Medical Technology Co stock appears to be undervalued.
The current stock price of HK$19.95 is trading 44.3% below its estimated GF Value™ of HK$35.80.
GuruFocus considers Zylox-Tonbridge Medical Technology Co to be Significantly Undervalued.
Key valuation signals for HKSE:02190:
EV-to-FCF: 14.66
GF Value™: HK$35.80 vs. price of HK$19.95 (44.3% below fair value)
Industry Position: 41.8% below the Medical Devices & Instruments median (#109 of 406)
No single metric tells the full story. See the HKSE:02190 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zylox-Tonbridge Medical Technology Co Ltd is principally engaged in providing solutions to patients and physicians with a product portfolio covering peripheral-vascular interventional devices and neurovascular interventional devices in China and other countries. The company's products include Thrombite Clot Retriever Device (Thrombite CRD), Ultrafree Drug Coated PTA Balloon Catheter (Ultrafree DCB), and others. The company derives majority of its revenue from PRC.
82GF Score
Get the complete analysis for HKSE:02190
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02190 has been successfully added to your 
